key: cord-0867259-ysky8ht3
authors: Zeitlinger, Markus; Idzko, Marco
title: Inhaled budesonide for early treatment of COVID-19
date: 2021-05-12
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(21)00215-0
sha: ea8bc28c9f261f2a16cdf056639a7359331aeb29
doc_id: 867259
cord_uid: ysky8ht3

nan

Ramakrishnan and colleagues 1 acknowledge the limitation of the open-label design, but do not discuss that, without clear rules, the primary outcome of the trial (urgent care visit, including emergency department assessment or hospitalisation) is very subjective, mainly driven by the patient's own perception of their course of disease. Patients not receiving the experimental treatment, which was presented to them as potentially beneficial at the time of informed consent, are likely to expect more complications than those given the active treatment.

Based on the mode of action, an improvement in blood oxygen saturation with budesonide would be expected. 4 This is the most objective endpoint for defining lung injury according to WHO; 5 however, no pattern in favour of budesonide was observed (no difference in proportion of days with oxygen saturation ≤94%, nor in participants with at least 1 day of oxygen saturation ≤94%). 1 The 11 participants who met the primary endpoint in the perprotocol group were defined by a mixture of very different medical events, namely three participants were symptomatically breathless, one developed diabetic ketoacidosis, one acute kidney injury, one suspected pulmonary embolism, and one suspected rib fracture. Four participants were seen at least twice by general practitioners or a paramedic crew, or both, of whom one was sent to the emergency department. Indeed, this one patient ultimately requiring ventilation was in the control group. However, diabetic ketoacidosis, acute kidney injury, suspected pulmonary embolism, or rib fractures hardly qualify as early COVID-19 complications. Furthermore, the fact that all three participants who were symptomatically breathless were in the control group, underlines the potential for self-assessment based bias, because no difference in oxygen saturation between the two groups could be found.

To us the main message from this Article is that budesonide was well tolerated without major side-effects or increased viral load, supporting further assessment in double-blind studies. Widespread use of a treatment with overestimated efficacy might lead to wrong decisions and risk perception in society and in individual patients.

We declare no competing interests.

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19

Blinding in randomised trials: hiding who got what

Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome

A minimal common outcome measure set for COVID-19 clinical research